Excess years of life lost to COVID-19 and other causes of death by sex, neighbourhood deprivation, and region in England and Wales during 2020: A registry-based study.


Journal

PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360

Informations de publication

Date de publication:
02 2022
Historique:
received: 30 07 2021
accepted: 05 01 2022
entrez: 15 2 2022
pubmed: 16 2 2022
medline: 26 2 2022
Statut: epublish

Résumé

Deaths in the first year of the Coronavirus Disease 2019 (COVID-19) pandemic in England and Wales were unevenly distributed socioeconomically and geographically. However, the full scale of inequalities may have been underestimated to date, as most measures of excess mortality do not adequately account for varying age profiles of deaths between social groups. We measured years of life lost (YLL) attributable to the pandemic, directly or indirectly, comparing mortality across geographic and socioeconomic groups. We used national mortality registers in England and Wales, from 27 December 2014 until 25 December 2020, covering 3,265,937 deaths. YLLs (main outcome) were calculated using 2019 single year sex-specific life tables for England and Wales. Interrupted time-series analyses, with panel time-series models, were used to estimate expected YLL by sex, geographical region, and deprivation quintile between 7 March 2020 and 25 December 2020 by cause: direct deaths (COVID-19 and other respiratory diseases), cardiovascular disease and diabetes, cancer, and other indirect deaths (all other causes). Excess YLL during the pandemic period were calculated by subtracting observed from expected values. Additional analyses focused on excess deaths for region and deprivation strata, by age-group. Between 7 March 2020 and 25 December 2020, there were an estimated 763,550 (95% CI: 696,826 to 830,273) excess YLL in England and Wales, equivalent to a 15% (95% CI: 14 to 16) increase in YLL compared to the equivalent time period in 2019. There was a strong deprivation gradient in all-cause excess YLL, with rates per 100,000 population ranging from 916 (95% CI: 820 to 1,012) for the least deprived quintile to 1,645 (95% CI: 1,472 to 1,819) for the most deprived. The differences in excess YLL between deprivation quintiles were greatest in younger age groups; for all-cause deaths, a mean of 9.1 years per death (95% CI: 8.2 to 10.0) were lost in the least deprived quintile, compared to 10.8 (95% CI: 10.0 to 11.6) in the most deprived; for COVID-19 and other respiratory deaths, a mean of 8.9 years per death (95% CI: 8.7 to 9.1) were lost in the least deprived quintile, compared to 11.2 (95% CI: 11.0 to 11.5) in the most deprived. For all-cause mortality, estimated deaths in the most deprived compared to the most affluent areas were much higher in younger age groups, but similar for those aged 85 or over. There was marked variability in both all-cause and direct excess YLL by region, with the highest rates in the North West. Limitations include the quasi-experimental nature of the research design and the requirement for accurate and timely recording. In this study, we observed strong socioeconomic and geographical health inequalities in YLL, during the first calendar year of the COVID-19 pandemic. These were in line with long-standing existing inequalities in England and Wales, with the most deprived areas reporting the largest numbers in potential YLL.

Sections du résumé

BACKGROUND
Deaths in the first year of the Coronavirus Disease 2019 (COVID-19) pandemic in England and Wales were unevenly distributed socioeconomically and geographically. However, the full scale of inequalities may have been underestimated to date, as most measures of excess mortality do not adequately account for varying age profiles of deaths between social groups. We measured years of life lost (YLL) attributable to the pandemic, directly or indirectly, comparing mortality across geographic and socioeconomic groups.
METHODS AND FINDINGS
We used national mortality registers in England and Wales, from 27 December 2014 until 25 December 2020, covering 3,265,937 deaths. YLLs (main outcome) were calculated using 2019 single year sex-specific life tables for England and Wales. Interrupted time-series analyses, with panel time-series models, were used to estimate expected YLL by sex, geographical region, and deprivation quintile between 7 March 2020 and 25 December 2020 by cause: direct deaths (COVID-19 and other respiratory diseases), cardiovascular disease and diabetes, cancer, and other indirect deaths (all other causes). Excess YLL during the pandemic period were calculated by subtracting observed from expected values. Additional analyses focused on excess deaths for region and deprivation strata, by age-group. Between 7 March 2020 and 25 December 2020, there were an estimated 763,550 (95% CI: 696,826 to 830,273) excess YLL in England and Wales, equivalent to a 15% (95% CI: 14 to 16) increase in YLL compared to the equivalent time period in 2019. There was a strong deprivation gradient in all-cause excess YLL, with rates per 100,000 population ranging from 916 (95% CI: 820 to 1,012) for the least deprived quintile to 1,645 (95% CI: 1,472 to 1,819) for the most deprived. The differences in excess YLL between deprivation quintiles were greatest in younger age groups; for all-cause deaths, a mean of 9.1 years per death (95% CI: 8.2 to 10.0) were lost in the least deprived quintile, compared to 10.8 (95% CI: 10.0 to 11.6) in the most deprived; for COVID-19 and other respiratory deaths, a mean of 8.9 years per death (95% CI: 8.7 to 9.1) were lost in the least deprived quintile, compared to 11.2 (95% CI: 11.0 to 11.5) in the most deprived. For all-cause mortality, estimated deaths in the most deprived compared to the most affluent areas were much higher in younger age groups, but similar for those aged 85 or over. There was marked variability in both all-cause and direct excess YLL by region, with the highest rates in the North West. Limitations include the quasi-experimental nature of the research design and the requirement for accurate and timely recording.
CONCLUSIONS
In this study, we observed strong socioeconomic and geographical health inequalities in YLL, during the first calendar year of the COVID-19 pandemic. These were in line with long-standing existing inequalities in England and Wales, with the most deprived areas reporting the largest numbers in potential YLL.

Identifiants

pubmed: 35167587
doi: 10.1371/journal.pmed.1003904
pii: PMEDICINE-D-21-03320
pmc: PMC8846534
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1003904

Déclaration de conflit d'intérêts

I have read the journal’s policy and the authors of this manuscript have the following competing interests: CG declares receiving support from Abbot and BMS towards this work, consulting fees from Amgen and AstraZeneca, honoraria from AstraZeneca, participation in Data Safety Monitoring Boards for several trials (TACTIC, DUAL-ACS, DANBLOCK, PROFID, RAPID NSTEMI, STEEER-AF), stock options with the European Heart Journal Quality of Care and Clinical Outcomes as Deputy Editor, and other financial interests with Wondr Medical. MKR declares Cell catapult and NovoNordisk consulting fees, unrelated to the content of the manuscript. None of the other authors have anything relevant to declare.

Références

J Epidemiol Community Health. 2018 Feb;72(2):140-147
pubmed: 29263178
Lancet Public Health. 2018 Dec;3(12):e567-e575
pubmed: 30389570
J Epidemiol Community Health. 2021 Mar;75(3):213-223
pubmed: 33060194
Mayo Clin Proc. 2021 Apr;96(4):952-963
pubmed: 33714592
Lancet Oncol. 2020 Aug;21(8):1023-1034
pubmed: 32702310
J Infect. 2020 Nov;81(5):797-801
pubmed: 32956730
PLoS One. 2020 Dec 10;15(12):e0242958
pubmed: 33301459
J Epidemiol Community Health. 2017 Sep;71(9):928-936
pubmed: 28790164
BMC Med. 2021 Mar 5;19(1):71
pubmed: 33663498
Lancet. 2021 May 22;397(10288):1915-1978
pubmed: 33965070
JAMA. 2021 Apr 2;:
pubmed: 33797550
Heart. 2020 Dec;106(24):1898-1905
pubmed: 33060261
BMJ. 2020 Apr 21;369:m1571
pubmed: 32317252
Fisc Stud. 2020 Jul 14;:
pubmed: 32836542
Heart. 2021 Jan;107(2):113-119
pubmed: 32988988
J Epidemiol Community Health. 2018 Jul;72(7):636-644
pubmed: 29555873
Health Econ. 2021 Mar;30(3):699-707
pubmed: 33368853
Infect Chemother. 2020 Jun;52(2):154-164
pubmed: 32537961
Lancet. 2020 Aug 8;396(10248):381-389
pubmed: 32679111
Lancet Respir Med. 2020 Dec;8(12):1167-1168
pubmed: 33007240
J Card Fail. 2020 Jun;26(6):464-465
pubmed: 32417376
BMC Public Health. 2020 Aug 14;20(1):1238
pubmed: 32795276
Lancet Reg Health Eur. 2021 Jun 08;7:100144
pubmed: 34557845

Auteurs

Evangelos Kontopantelis (E)

Division of Informatics, Imaging and Data Sciences, University of Manchester, Manchester, England.
NIHR School for Primary Care Research, University of Oxford, Oxford, England.
Health Organisation, Policy and Economics (HOPE) Research Group, University of Manchester, Manchester, England.

Mamas A Mamas (MA)

Division of Informatics, Imaging and Data Sciences, University of Manchester, Manchester, England.
Keele Cardiovascular Research Group, Centre for Prognosis Research, Keele University, Keele, England.
Department of Cardiology, Jefferson University, Philadelphia, Pennsylvania, United States of America.

Roger T Webb (RT)

Centre for Mental Health & Safety, Division of Psychology & Mental Health, University of Manchester and Manchester Academic Health Sciences Centre (MAHSC), England.
NIHR Greater Manchester Patient Safety Translational Research Centre, Manchester, England.

Ana Castro (A)

Department of Health Sciences, University of York, England.

Martin K Rutter (MK)

Division of Diabetes, Endocrinology and Gastroenterology, School of Medical Sciences, University of Manchester, Manchester, England.
Diabetes, Endocrinology and Metabolism Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, England.

Chris P Gale (CP)

Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, England.
Leeds Institute for Data Analytics, University of Leeds, Leeds, England.
Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, England.

Darren M Ashcroft (DM)

NIHR School for Primary Care Research, University of Oxford, Oxford, England.
NIHR Greater Manchester Patient Safety Translational Research Centre, Manchester, England.
Division of Pharmacy & Optometry, University of Manchester, Manchester, England.

Matthias Pierce (M)

Centre for Women's Mental Health, Division of Psychology and Mental Health, University of Manchester, Manchester, England.

Kathryn M Abel (KM)

Centre for Women's Mental Health, Division of Psychology and Mental Health, University of Manchester, Manchester, England.

Gareth Price (G)

Manchester Cancer Research Centre, The Christie NHS Foundation Trust, University of Manchester, Manchester, England.

Corinne Faivre-Finn (C)

Manchester Cancer Research Centre, The Christie NHS Foundation Trust, University of Manchester, Manchester, England.

Harriette G C Van Spall (HGC)

Department of Medicine and Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada.

Michelle M Graham (MM)

Division of Cardiology, University of Alberta and Mazankowski Alberta Heart Institute, Edmonton, Alberta, Canada.

Marcello Morciano (M)

NIHR School for Primary Care Research, University of Oxford, Oxford, England.
Health Organisation, Policy and Economics (HOPE) Research Group, University of Manchester, Manchester, England.

Glen P Martin (GP)

Division of Informatics, Imaging and Data Sciences, University of Manchester, Manchester, England.

Matt Sutton (M)

NIHR School for Primary Care Research, University of Oxford, Oxford, England.
Division of Population Health, Health Services Research & Primary Care, University of Manchester, Manchester, England.

Tim Doran (T)

Department of Health Sciences, University of York, England.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH